Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-24

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a controlled investigation, with randomization of the patients, which aims at demonstrating the efficacy of device RGn600 in treating patients with mild-to-moderate Alzheimer's disease (AD). RGn600 is a non-invasive medical device which is applied on the head (helmet) and on the abdomen (abdominal belt). It combines 2 technologies:

* PhotoBioModulation (PBM), which involves exposure to light from the red to near-infrared wavelengths using lasers and Light Emitting Diodes (LEDs)
* Static Magnetic Stimulation (SMS), which consists in the application of a static magnetic field.

Considering previous investigations, this innovative technology could reduce inflammation on the brain-gut axis, implicated in the development of Alzheimer's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Five Lives MED to Improve Cognitive Function in Mild Cognitive Impairment

NCT06598163

Mild Cognitive Impairment

RECRUITING NA

Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease

NCT02359864

Alzheimer's Disease

TERMINATED NA

Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease

NCT02991235

Alzheimer Disease

UNKNOWN NA

Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants

NCT02792179

Alzheimer's Disease

COMPLETED PHASE1

A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease

NCT05478031

Alzheimer Disease

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This multicentric investigation is planned to include 108 patients in France who will be followed up to 52 weeks.

Patients meeting all eligibility criteria will be randomized on a 1: 1 ratio into one of the two following treatment groups: active RGn600 device or sham device (inactivated RGn600). The site investigation teams and patients/caregivers will be blinded. The device will be applied to the patients during 26 weeks through 20-min onsite sessions following the below pattern:

* 5 treatment sessions per week from Week 1 (W1) to W8
* 3 treatment sessions per week from W9 to W16
* 2 treatment sessions per week from W17 to W26 Throughout the investigation, patients will be treated per randomization with the device initially allocated by the IWRS.

Follow-up will continue up to W52 ± 2 weeks

At inclusion visit, after verification of the eligibility criteria, data regarding patients will be collected: demographic data, date of AD diagnosis, comorbidities, concomitant medications, sociological data. A blood sample for APOE genotyping will be also performed.

Endpoints will be evaluated during 4 onsite visits at Day 0 (Inclusion, randomization to the active or sham group and first treatment session), W8 (last treatment session of), W26 (last treatment session of) and W52 ± 2 weeks. During these visits:

* Patient's cognition and autonomy will be assessed through neurological scales and/or neuropsychological tests
* Patient's quality of life and medico-economic interest of RGn600 treatment with regards to healthcare consumption will be assessed through questionnaires fulfilled by the patient himself/herself with the help of his/her caregiver
* The safety of RGn600 will be assessed : collection of all AEs and device deficiencies, blood samples for safety analysis, clinical exams

Within the context of this investigation, a biobank will be created based on blood, fecal and saliva samples of patients included by Toulouse University Hospital Gerontopole site:

* Blood samples will be collected for all patients included by this site (at D0, W26 and W52)
* Fecal samples will be collected for the first 30 consecutive patients included by this site (at D0, W26 and W52).
* Saliva samples will be collected for the patients included by this site after the substantial modification approval (at D0, W26 and W52).

The biobank will be located at the site. The objective of this biobank will be to perform subsequent analysis on blood samples of AD blood markers. Other analyses might be conducted on blood, fecal and saliva samples as well such as Inflammatory blood markers (iAGE), fecal microbiota and metabolome and salivary micro RiboNucleic Acid (microRNAs)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

An interventional, prospective, multicentric, randomized, comparative and double-blinded pivotal clinical investigation

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active RGn600

RGn600 with a 10 Hz-pulsed wave mode light emission

Group Type EXPERIMENTAL

RGn600

Intervention Type DEVICE

RGn600 with a 10 Hz-pulsed wave mode light emission

Sham

Inactivated RGn600

Group Type SHAM_COMPARATOR

RGn600 Sham

* Patient protected by a French legal measure ("sauvegarde de justice", "tutelle" or "curatelle")
* Patient deprived of liberty or hospitalized without consent
* Non-menopausal woman
* Patient taking a disease-modifying treatment such as the Leqembi® or any other disease-modifying treatment that may be authorized in France before the end of the study
* Patient living in a medical facility
* Patient who experienced a surgery at the treatment application area (abdomen or head) within 3 months prior inclusion
* Patient with skin lesions on the treatment application area (abdomen or head)
* Patient with a short-term life-threatening pathology (e.g., evolving cancer; non-stable heart failure; severe hepatic, renal or respiratory failure, etc.)
* Patient diagnosed with a stroke within 3 months prior inclusion
* Patients with ferromagnetic material (i.e., iron, nickel, cobalt or any metal alloy) on or near the head or abdomen, or implanted with a pacemaker
* Patient with a risk of epileptic seizure
* Patient with a genetic form of AD
* Patient with major physical or neurosensorial disorders that may interfere with neurological assessments
* Patient with chronic psychosis or psychotic episodes
* Patient addicted to alcohol or drugs
* Patient with known and non-supplemented vitamin B12 and folic acid deficiencies
* Patient with known untreated hypothyroidism
* Patient who participated to another investigation/study involving the use of an investigational medical device/drug within the 30 days prior inclusion
* Patient not able to meet treatment sessions as deemed by the investigator
* Patient not able to complete requested investigation assessments as deemed by the investigator.

Minimum Eligible Age

55 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No